Cargando…

Prostatic Artery Embolization for the Treatment of Benign Prostate Hyperplasia: Initial Experience From Bahrain

Introduction: Benign prostate hyperplasia (BPH) is a common problem in elderly men. The current gold standard is surgical transurethral resection of the prostate (TURP). Prostatic artery embolization (PAE) is an alternative treatment of BPH, which avoids surgical complications. This is a single-cent...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamed Ibrahim, Wael, Abduljawad, Hiba, Mohamed, Hosameldin, Jamsheer, Noora, Elsayed Elnaggar, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958120/
https://www.ncbi.nlm.nih.gov/pubmed/35371804
http://dx.doi.org/10.7759/cureus.22593
_version_ 1784676883127861248
author Hamed Ibrahim, Wael
Abduljawad, Hiba
Mohamed, Hosameldin
Jamsheer, Noora
Elsayed Elnaggar, Mohamed
author_facet Hamed Ibrahim, Wael
Abduljawad, Hiba
Mohamed, Hosameldin
Jamsheer, Noora
Elsayed Elnaggar, Mohamed
author_sort Hamed Ibrahim, Wael
collection PubMed
description Introduction: Benign prostate hyperplasia (BPH) is a common problem in elderly men. The current gold standard is surgical transurethral resection of the prostate (TURP). Prostatic artery embolization (PAE) is an alternative treatment of BPH, which avoids surgical complications. This is a single-center prospective study from the Kingdom of Bahrain to evaluate the effectiveness of PAE. Methods: This prospective, single-center study included consecutive patients eligible for PAE. Patients were evaluated at one, three, six, and 12 months. Clinical success was defined as a decrease of International Prostate Symptom Score (IPSS) ≥ 3 points, quality of life (QoL) score ≤ 3 or decrease by three points, and no need for surgical intervention. Correlation between prostate-specific antigen (PSA) at 24 hours and reduction in prostate volume and IPSS score was also assessed. Results: A total of 29 patients underwent the procedure between June 2015 and August 2018. Bilateral embolization was achieved in 26 patients. Clinical success was achieved in 26 patients (89.65%). No major adverse events were encountered. Significant improvement for storage (−4.54 ± 2.93, p < 0.005) and voiding symptoms score (−7.54 ± 4.74, p <0.005) were seen. There was no significant correlation between 24 hours PSA and reduction of the size of prostate and IPSS score at 12 months. Conclusion: PAE is a minimally invasive procedure that is safe and effective for the management of BPH. PAE is effective for the management of both storage and voiding symptoms.
format Online
Article
Text
id pubmed-8958120
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-89581202022-03-31 Prostatic Artery Embolization for the Treatment of Benign Prostate Hyperplasia: Initial Experience From Bahrain Hamed Ibrahim, Wael Abduljawad, Hiba Mohamed, Hosameldin Jamsheer, Noora Elsayed Elnaggar, Mohamed Cureus Radiology Introduction: Benign prostate hyperplasia (BPH) is a common problem in elderly men. The current gold standard is surgical transurethral resection of the prostate (TURP). Prostatic artery embolization (PAE) is an alternative treatment of BPH, which avoids surgical complications. This is a single-center prospective study from the Kingdom of Bahrain to evaluate the effectiveness of PAE. Methods: This prospective, single-center study included consecutive patients eligible for PAE. Patients were evaluated at one, three, six, and 12 months. Clinical success was defined as a decrease of International Prostate Symptom Score (IPSS) ≥ 3 points, quality of life (QoL) score ≤ 3 or decrease by three points, and no need for surgical intervention. Correlation between prostate-specific antigen (PSA) at 24 hours and reduction in prostate volume and IPSS score was also assessed. Results: A total of 29 patients underwent the procedure between June 2015 and August 2018. Bilateral embolization was achieved in 26 patients. Clinical success was achieved in 26 patients (89.65%). No major adverse events were encountered. Significant improvement for storage (−4.54 ± 2.93, p < 0.005) and voiding symptoms score (−7.54 ± 4.74, p <0.005) were seen. There was no significant correlation between 24 hours PSA and reduction of the size of prostate and IPSS score at 12 months. Conclusion: PAE is a minimally invasive procedure that is safe and effective for the management of BPH. PAE is effective for the management of both storage and voiding symptoms. Cureus 2022-02-25 /pmc/articles/PMC8958120/ /pubmed/35371804 http://dx.doi.org/10.7759/cureus.22593 Text en Copyright © 2022, Hamed Ibrahim et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Radiology
Hamed Ibrahim, Wael
Abduljawad, Hiba
Mohamed, Hosameldin
Jamsheer, Noora
Elsayed Elnaggar, Mohamed
Prostatic Artery Embolization for the Treatment of Benign Prostate Hyperplasia: Initial Experience From Bahrain
title Prostatic Artery Embolization for the Treatment of Benign Prostate Hyperplasia: Initial Experience From Bahrain
title_full Prostatic Artery Embolization for the Treatment of Benign Prostate Hyperplasia: Initial Experience From Bahrain
title_fullStr Prostatic Artery Embolization for the Treatment of Benign Prostate Hyperplasia: Initial Experience From Bahrain
title_full_unstemmed Prostatic Artery Embolization for the Treatment of Benign Prostate Hyperplasia: Initial Experience From Bahrain
title_short Prostatic Artery Embolization for the Treatment of Benign Prostate Hyperplasia: Initial Experience From Bahrain
title_sort prostatic artery embolization for the treatment of benign prostate hyperplasia: initial experience from bahrain
topic Radiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958120/
https://www.ncbi.nlm.nih.gov/pubmed/35371804
http://dx.doi.org/10.7759/cureus.22593
work_keys_str_mv AT hamedibrahimwael prostaticarteryembolizationforthetreatmentofbenignprostatehyperplasiainitialexperiencefrombahrain
AT abduljawadhiba prostaticarteryembolizationforthetreatmentofbenignprostatehyperplasiainitialexperiencefrombahrain
AT mohamedhosameldin prostaticarteryembolizationforthetreatmentofbenignprostatehyperplasiainitialexperiencefrombahrain
AT jamsheernoora prostaticarteryembolizationforthetreatmentofbenignprostatehyperplasiainitialexperiencefrombahrain
AT elsayedelnaggarmohamed prostaticarteryembolizationforthetreatmentofbenignprostatehyperplasiainitialexperiencefrombahrain